What is 5-Amino-1MQ?
5-Amino-1MQ is a small molecule studied as an inhibitor of nicotinamide N-methyltransferase (NNMT). Its featured evidence concerns cultured adipocytes and obese mice, rather than demonstrated weight loss in people.
Biological role or research focus
NNMT and adipose metabolism.
These experiments do not establish a human weight-loss effect, a clinical regimen, or long-term safety. Different counterions or formulations also need separate identity checks.
Names you may encounter
5-amino-1-methylquinolinium
Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.
- Class / identity
- Small-molecule NNMT inhibitor; not a peptide
- Research focus
- NNMT and adipose metabolism
- Featured evidence
- Animal and cell study
- Source check
- October 4, 2026
Quick answers
- Is 5-Amino-1MQ FDA approved?
- No. No FDA-approved drug contains 5-Amino-1MQ. Source ↗
- Is 5-Amino-1MQ safe?
- 5-Amino-1MQ is an experimental NNMT-blocking small molecule, not a peptide. It has never been safety-tested in people; what is known comes from cell and mouse studies. Human safety data: none. The Risks & interactions section below lists what is known. Read the risks ↓
- Is 5-Amino-1MQ banned in sport?
- Very likely. The 2026 World Anti-Doping Agency (WADA) Prohibited List does not name it, but it appears to fall under a banned class (S0 Non-approved substances). Source ↗
- Has the FDA taken action over 5-Amino-1MQ?
- Yes. Our records list 1 FDA action naming it, most recently on January 20, 2026: FDA warning letter to an outsourcing facility (GenoGenix) naming 5-Amino-1MQ (5-amino-1-methylquinolinium iodide) as a bulk substance not eligible for 503B compounding. Source ↗
What does the evidence show?
Evidence map
Every study featured on this page, grouped by what was actually tested. Human studies count most; animal and cell results often do not carry over to people.
| Study | Type | Population / model |
|---|---|---|
| NNMT inhibition in diet-induced obesity (2018) | Animal and cell study | Cultured adipocytes and mice with high-fat-diet-induced obesity. |
| NNMT inhibition · aged muscle injury (2019) | 24-month-old mice with chemically induced tibialis-anterior injury, plus cultured mouse myoblasts. |
Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.
Animal and cell study · 2018
NNMT inhibition in diet-induced obesity
What did this publication test, and what did it find?
- Population / model
- Cultured adipocytes and mice with high-fat-diet-induced obesity.
- Study design
- Membrane-permeability and enzyme-selectivity experiments followed by metabolic measurements in cells and a short mouse treatment experiment.
- Main finding
- The investigators reported reduced fat synthesis in adipocytes and lower body weight, white-adipose mass, and cholesterol in treated obese mice, without a change in total food intake.
- Limits & context
- These experiments do not establish a human weight-loss effect, a clinical regimen, or long-term safety. Different counterions or formulations also need separate identity checks.
Related NNMT-pathway animal study · 2019
NNMT inhibition · aged muscle injury
What did a separate muscle-regeneration experiment test?
- Population / model
- 24-month-old mice with chemically induced tibialis-anterior injury, plus cultured mouse myoblasts.
- Study design
- Saline versus a small-molecule NNMT inhibitor for one or three weeks; stem-cell activity, muscle-fiber size, and contractile function measured.
- Main finding
- Treated mice showed increased stem-cell proliferation and fusion, larger regenerating fibers, and approximately 70% higher peak torque than controls in the tested muscle.
- How to read it
- This extends NNMT-pathway research beyond the earlier obesity model; it is not a human sarcopenia trial.
- Limits & context
- The abstract names the intervention as NNMTi without stating its exact chemical identity. Compound identity must be checked in the full methods before treating it as direct evidence for a specific 5-amino-1MQ product. Injury-model findings do not establish healthy-human strength or recovery.
Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.
Registered human trials
No study naming 5-Amino-1MQ as an intervention was found on ClinicalTrials.gov when we last checked (November 14, 2026). That means no registered human trial, not proof that none has ever been done elsewhere.
Search additional PubMed records ↗Risks & interactions
5-Amino-1MQ is an experimental NNMT-blocking small molecule, not a peptide. It has never been safety-tested in people; what is known comes from cell and mouse studies.
No published human safety studies were found. A short study in obese mice reported no observable adverse effects, which cannot rule out organ toxicity, drug interactions or rare harms in people.
Unassessed: no human safety data
It isn't approved, so there is no official list of who should avoid it, and no human safety studies have been published. No condition is tagged, but that does not make it safe for anyone. If a condition applies to you, talk to a doctor or pharmacist first.
Who should not use it
There is no official list, because it has never been approved as a medicine. That is not a sign it is safe for anyone: its risks have not been studied enough to know who is most at risk.
Summarized from published studies with AI assistance; not reviewed by a clinician. Not a complete list, and not medical advice: talk to a doctor or pharmacist about your own situation. Checked 2026-10-10. Sources: NNMT inhibitors reverse diet-induced obesity in mice (2018) ↗
Safety & what remains unknown
No observable adverse effects were reported in the short mouse experiment. That observation cannot exclude organ toxicity, interactions, or uncommon harms in people.
Evidence boundaries
These experiments do not establish a human weight-loss effect, a clinical regimen, or long-term safety. Different counterions or formulations also need separate identity checks.
Regulatory status
- U.S. FDA approval
- Not approved
No FDA-approved drug containing this substance found in Drugs@FDA (openFDA data updated 2026-10-07). source - FDA compounding (503A bulk list)
- Not on FDA’s compounding lists
Not found on FDA's 503A category 1, 2 or 3 lists (updated May 14, 2026) or the category 2 safety-risk page (updated April 22, 2026). source - World Anti-Doping Agency (2026)
- Likely prohibited under a class rule · S0 Non-approved substances
Not named. S0 prohibits (at all times) any pharmacological substance not covered by another section and with no current approval by any government health authority for human therapeutic use; no such approval was found, so it is likely covered. source
FDA actions
- FDA warning letter to an outsourcing facility (GenoGenix) naming 5-Amino-1MQ (5-amino-1-methylquinolinium iodide) as a bulk substance not eligible for 503B compounding. (2026-01-20) source
Checked October 28, 2026. Rules change; follow the source links for the current status. Regulatory tracker.
This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.
Research context & identity
This profile covers preclinical metabolic research. 5-Amino-1MQ is included as a related compound because it appears in peptide catalogs; its chemistry is not peptidic.
New editorial updates
New source discoveries
Links appear automatically. Unreviewed discoveries are not verified medical findings.
Sources & supplier listings
Seller lab-report checks and prices are available to members. Sign up free
Biology & proposed mechanism
The study investigated whether inhibiting NNMT changes cellular metabolite availability and fat synthesis. Target engagement and a mouse response are separate questions from effective human treatment.
Questions worth asking
- Is 5-Amino-1MQ a peptide?
- What material, population, and route were actually studied?
- These experiments do not establish a human weight-loss effect, a clinical regimen, or long-term safety. Different counterions or formulations also need separate identity checks.
- What adverse effects, uncertainty, and conflicts of interest does the original source report?
Video & podcast discussions: members library
Frequently asked questions
Is 5-Amino-1MQ a peptide?
No. It is a small-molecule NNMT inhibitor. Placement in a research-peptide shop does not change its molecular class.
Does the publication verify a supplier’s product?
No. The tested material and a commercial listing need separate identity and batch checks. A research-use disclaimer does not establish clinical suitability.
References & editorial record
Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation.
